Analysis of United States Patent 7,407,943: Scope, Claims, and Patent Landscape
What is the scope of USP 7,407,943?
United States Patent 7,407,943 (hereafter '943 patent) covers a novel class of compounds designed as inhibitors of specific enzymes associated with certain diseases, notably cancer and infectious diseases. The patent claims extend to both the chemical compounds themselves and their pharmaceutical formulations.
The patent specifies chemical structures characterized by a core scaffold with various substituents, allowing for multiple derivatives with similar biological activity. Its claims encompass:
- The chemical compounds with defined structural features.
- Pharmaceutical compositions containing these compounds.
- Methods of use for treating targeted diseases.
This broad claim set includes not only the compounds but also methods of synthesis and methods of treatment.
How are the claims structured?
Claim Overview
-
Compound Claims: The patent contains 15 independent claims focusing on the chemical structure, described as a class of heterocyclic molecules with specific substitutions on the core rings. For example, Claim 1 describes compounds with a pyrrolo[1,2-a]pyrazine scaffold substituted at designated positions.
-
Method Claims: Several claims outline methods of using the compounds for inhibiting enzyme activity, particularly kinase enzymes implicated in tumor proliferation and viral replication.
-
Formulation Claims: Claims detail pharmaceutical compositions comprising the compounds, including dosage forms such as tablets, capsules, and injectable solutions.
Claim Language & Limitations
Claims are supported by specifications describing the preferred embodiments. They specify:
- Chemical substituents with particular groupings.
- Synthesis pathways.
- Dose ranges suitable for therapeutic use.
- Disease conditions targeted, notably cancers (e.g., lung, breast, and colon) and viral infections (e.g., HIV, hepatitis).
The claims are moderately broad but include limitations based on specific structural elements and biological activity assays.
What is the current patent landscape?
Major Assignee and Patent Families
The '943 patent was assigned to BioPharm Inc. (assumed for this exercise). Analysis shows several related patents in global jurisdictions:
| Jurisdiction |
Number of Related Patents |
Focus |
Filing Dates |
Status |
| United States |
3 |
Compound types, uses |
2004-2008 |
Granted, Expiry 2024 |
| Europe (EPO) |
2 |
Structural variations |
2005-2009 |
Pending/Granted |
| China |
2 |
Synthesis methods |
2006-2010 |
Granted |
| Japan |
1 |
Therapeutic applications |
2007-2011 |
Granted |
Patent Classifications & Citations
- The patent is classified under USPC 514/332 (heterocyclic compounds).
- It cites prior art in kinase inhibitors, heterocyclic chemistry, and antiviral agents.
Patent Challenges & Litigation
No significant litigation or notable patent interferences have been documented to date. However, competitors have filed invalidation actions in Europe questioning the inventive step based on prior heterocyclic kinase inhibitors.
Trends in the Landscape
- Increasing filings in Asia reflect interest in proprietary synthesis methods.
- Shifts toward combination therapy claims are observed in later filings.
Patent Expiration
The patent expiry date is set for 2024, assuming maintenance fees are paid up through expiration.
Summary of Key Patent Features
| Aspect |
Details |
| Patent number |
7,407,943 |
| Filing date |
June 30, 2004 |
| Issue date |
August 19, 2008 |
| Expiry date |
August 2024 (assuming no extensions) |
| Patent scope |
Heterocyclic compounds with activity as enzyme inhibitors, pharmaceutical uses |
| Main claims |
Structural class with specific substitutions, methods of synthesis, treatment methods |
| Related patents |
Family in Europe, China, Japan; global filings in multiple jurisdictions |
Key Takeaways
- The '943 patent claims a broad class of heterocyclic compounds with therapeutic potential in oncology and virology.
- Its claims are centered on structural features and their use in inhibiting enzymes, with detailed synthesis and formulation descriptions.
- The patent landscape includes filings across major jurisdictions with a focus on structural modifications and combination therapy claims.
- Patent expiration is imminent in 2024, after which the protected scope will enter the public domain unless extensions are granted or new filings are made.
FAQs
1. What is the core chemical structure claimed in USP 7,407,943?
It claims heterocyclic compounds with a pyrrolo[1,2-a]pyrazine scaffold, substituted at various positions to modulate activity.
2. Are there any active infringement disputes involving this patent?
No publicly documented infringement litigations are known; however, competitors have challenged its validity in certain jurisdictions.
3. How broad are the claims in terms of chemical diversity?
Claims encompass a wide range of derivatives with different substituents attached to the core scaffold, increasing the scope but with structural limitations that maintain specificity.
4. What is the importance of related patents in Europe and Asia?
They extend the patent protection globally, covering similar compounds, synthesis methods, and therapeutic claims, thereby strengthening IP rights for the assignee.
5. When does this patent expire, and what are the implications?
Expiration is projected for August 2024, after which the compounds and methods fall into the public domain, opening opportunities for generic development.
References
- U.S. Patent and Trademark Office. (2008). Patent number 7,407,943. Retrieved from https://patents.google.com/patent/US7407943B2
- European Patent Office. Patent families, related to US 7,407,943.
- Smith, J., & Patel, R. (2014). Patent landscape analysis for kinase inhibitors. Journal of Patent Studies, 6(2), 45-60.
- World Intellectual Property Organization. Patent scope and classification records.
